<DOC>
	<DOCNO>NCT01989910</DOCNO>
	<brief_summary>A pilot study compare efficacy safety raltegravir-based versus efavirenz-based combination therapy treatment-naïve patient HIV-1 infection .</brief_summary>
	<brief_title>Compare Efficacy Safety Raltegravir Versus Efavirenz Combination Therapy Treatment-naïve HIV-1 Patients</brief_title>
	<detailed_description>A single-center , prospective , randomize , open label , parallel study compare efficacy safety raltegravir-based versus efavirenz-based plus optimal nucleoside reverse-transcriptase inhibitor ( NRTIs ) backbone combination therapy treatment-naïve patient HIV-1 infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients infected HIV1 Patients yet receive treatment HIV Patients HIV viral RNA exceed 5000 copy per ml Ages least 20 year Patients acute decompensated chronic hepatitis Patients chronic hepatitis serum aminotransferase concentration five time upper limit normal range Patients renal insufficiency ( need dialysis serum creatinine concentration twice upper limit normal range Patients medical disorder use study medication contraindicate Pregnant breastfeed woman Patients lack expectation maintain assign study medication study period Patients receive therapy investigational drug previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Efavirenz</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Combination antiretroviral therapy</keyword>
</DOC>